4 results about "Lymphoid Tumor" patented technology

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

The application relates to a kind of automatic classification methods of children lymphoma type based on imageomics, belong to artificial intelligence technical field.It includes the following steps: collecting children lymphoma CT image, constructs data set;The original three-dimensional CT image is preprocessed and adaptively gray window is adjusted, and preprocessed three-dimensional CT image data is obtained;Imageomics feature extraction and region perception gradient weighted screening are carried out, and the comprehensive screening score of each feature is obtained;A classification model of children lymphoma type is constructed, the enhanced imageomics feature, the clinical prior feature and the deep feature modulated by region perception weight are fused, the adaptive fusion of features is realized by using dynamic gating mechanism, and the category probability vector is output;The model is trained and optimized by a composite loss function, and a trained model is obtained;The CT image of children lymphoma to be classified is input into the trained model, and a classification result is obtained.The application can improve the accuracy of automatic classification of children lymphoma type.

The application belongs to the technical field of medical image processing and computer-aided diagnosis, and discloses an orbital lymphoma and inflammatory pseudotumor classification method, system, device and terminal, in the obtained orbital DCE-MRI image, the tumor region and the eye cone triangular region in the original image are manually segmented and pretreated; the neural network is used for extracting the features of the tumor region, and the features are subjected to clustering statistical analysis as the tumor region features; the eye cone triangular region is subjected to feature extraction as a similarity judgment standard, and the self-classification and self-recovery network is used for extracting the eye cone region features; the original image is used as the input network and combined with the features of the tumor region and the eye cone triangular region to train the network model; the multi-modal orbital data is input into the classification model for processing, so that the orbital lymphoma and inflammatory pseudotumor are classified. The application comprehensively considers the texture features of the tumor and the depth features of the eye cone region, effectively improves the prediction accuracy, and has the characteristics of high accuracy.

The present application provides a polypeptide or a pharmaceutically acceptable salt thereof, wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The polypeptide or the pharmaceutically acceptable salt thereof can bind to PD-1 and CTLA-4, and is used for effectively inhibiting PD-1 and CTLA-4. Thus, the polypeptide or the pharmaceutically acceptable salt thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases mediated by PD-1 and / or CTLA-4 (such as tumors or cancers, for example, non-small cell lung cancer, melanoma, lymphoma and leukemia, etc.).